Know Cancer

forgot password

Multicenter Phase II Study for Zevalin® in Patients With Relapsed/Refractory Indolent Lymphomas: Extranodal Marginal Lymphoma of MALT Type, Nodal Marginal Zone B-Cell Lymphoma, and Splenic Marginal B-Cell Lymphoma

Phase 2
18 Years
Not Enrolling

Thank you

Trial Information

Multicenter Phase II Study for Zevalin® in Patients With Relapsed/Refractory Indolent Lymphomas: Extranodal Marginal Lymphoma of MALT Type, Nodal Marginal Zone B-Cell Lymphoma, and Splenic Marginal B-Cell Lymphoma

^90 Y Ibritumomab tiuxetan and rituximab are both designed to attach to lymphoma cells,
causing them to die.

Before you can start treatment on this study, you will have what are called "screening
tests." These tests will help the doctor decide if you are eligible to take part in this
study. You will have a physical exam. Your blood (about 2 to 3 teaspoons) and urine will
be collected for routine tests. You will have a chest x-ray and computerized tomography
(CT) scans of the neck, chest, abdomen, and pelvis. You will have a bone marrow aspirate and
biopsy performed. To collect a bone marrow aspirate and biopsy, an area of the hip or chest
bone is numbed with anesthetic, and a small amount of bone marrow and bone is withdrawn
through a large needle. Women who are able to have children must have a negative blood
pregnancy test.

The study doctors will first make sure that your disease has not spread too much and is not
too severe to require immediate treatment with chemotherapy before you can begin treatment
on this study. If you are found to be eligible to take part in this study, you will be
given Benadryl (diphenhydramine) by vein, and you will be given Tylenol (acetaminophen) by
mouth before each dose of rituximab. This is done to help decrease the risk of developing
side effects of rituximab. You will then receive 1 dose of rituximab by vein over 6 to 8
hours on Day 1 of treatment. After treatment with rituximab, you will then be given a
radioactive antibody, ^111 In Ibritumomab tiuxetan (this is a radioactive agent that binds
to rituximab to help with imaging exams), by vein over about 10 minutes. This is so
researchers can use a special camera to see where the drug is in your body.

You will have imaging performed (with the special camera) on Day 1 and on either Day 2 or
Day 3. On Day 8, you will receive a second dose of rituximab. This will then be followed by
a dose ^90 Y Ibritumomab tiuxetan of given by vein over 10 minutes. This completes the

If you experience intolerable side effects while on this study, you may be removed from this
study. The study doctor will then offer other treatment options to you.

For your follow-up, you will have blood (about 2 tablespoons) drawn once a week for the
first 3 months, then every 3 months for 1 year, and then every 4 months for the second year.
At these visits, you may also have CT scans, x-rays, and bone marrow biopsies and aspirates
performed, if needed.

This is an investigational study. ^90 Y Ibritumomab tiuxetan and rituximab have been
approved by the FDA for the treatment of indolent B-cell lymphoma. Up to 35 patients will
take part in this multicenter study. Up to 15 will be enrolled at M. D. Anderson.

Inclusion Criteria:

1. No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or
Mitomycin C) prior to study initiation, and fully recovered from acute toxicities
associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.

2. Previously treated patients with a histology of refractory/relapsed indolent
lymphomas including: (a) Extranodal marginal lymphoma of MALT type; (b) Nodal
Marginal zone B-cell lymphoma (+/- monocytoid cells); (c) Splenic marginal B-cell
lymphoma (+/- villous lymphocytes).

3. Signed informed consent

4. Age >/= 18 years

5. Expected survival >/= 3 months

6. Pre-study Zubrod performance status of 0, 1, or 2

7. Acceptable hematologic status within two weeks prior to patient registration,
including: (a) Absolute neutrophil count ([segmented neutrophils + bands] * total
white blood count (WBC)) >/= 1,500/mm^3; (b) Platelet counts >/= 100,000/mm^3.

8. Female patients who are not pregnant or lactating

9. Men and women of reproductive potential who are following accepted birth control
methods (as determined by the treating physician)

10. Patients previously on Phase II drugs if no long-term toxicity is expected, and the
patient has been off the drug for eight or more weeks with no significant post
treatment toxicities observed

11. Patients determined to have < 25% bone marrow involvement with lymphoma within six
weeks of registration (define measurement of a bone marrow aspirate or biopsy) (This
criteria must be strictly met for adequate patient safety.)

12. Patient should have at least one lesion measuring >/= 2 cm in a single dimension.

Exclusion Criteria:

1. Prior myeloablative therapies with autologous bone marrow transplantation (ABMT) or
peripheral blood stem cell (PBSC) rescue.

2. Platelet count< 100,000 cells/mm^3.

3. Presence of hypocellular bone marrow.

4. Patients with history of failed stem cell collection.

5. Prior radioimmunotherapy

6. Presence of Central Nervous System (CNS) lymphoma

7. Patients with HIV.

8. Patients with pleural effusion

9. Patients with abnormal liver function: total bilirubin > 2.0 mg/dL

10. Patients with abnormal renal function: serum creatinine > 2.0 mg/dL

11. Patients who have received prior external beam radiation therapy to > 25% of active
bone marrow (involved field or regional)

12. Patients who have received short-acting growth factor support (Leukine, Neupogen,
Procrit) within 2 weeks prior to treatment or long-acting growth-factor support
(Aranesp), Neulasta) within 4 weeks prior to treatment.

13. Serious nonmalignant disease or infection which, in the opinion of the investigator
and/or the sponsor, would compromise other protocol objectives

14. Major surgery, other than diagnostic surgery, within four weeks

15. Evidence of transformation in the latest biopsy

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate

Outcome Description:

Objective response rate (ORR) = number of participants out of all participating with Complete Response (CR) + Partial Response (PR) as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial response (PR) must have ≥ 30% decrease in the sum of longest diameter of all target lesions, from the baseline sum. Complete response (CR) must have disappearance of all target and non-target lesions. Response assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scans, every 3 months for the first year and every 6 months up to 3 years following.

Outcome Time Frame:

Evaluation 4 weeks after administration of Zevalin up to 3 years

Safety Issue:


Principal Investigator

Felipe Samaniego, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

April 2006

Completion Date:

March 2011

Related Keywords:

  • Lymphoma
  • Indolent Lymphoma
  • Extranodal Marginal
  • Nodal Marginal Zone
  • Splenic Marginal
  • MALT Type
  • Zevalin
  • Ibritumomab Tiuxetan
  • Rituximab
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, B-Cell, Marginal Zone



UT MD Anderson Cancer CenterHouston, Texas  77030